

**EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than payment of the issue fee. John M. Covert authorized this examiner's amendment in a telephone interview on Sep. 16, 2009.

***In The Specification***

At page 17, line 19, and at page 23, line 15, have both been changed to read:  
-- 1-isopropyl-6,7-methylenedioxy-4-(2,3-dihydro-5-benzofuranyl)quinazolin- --.

***In The Claims***

In claim 18, line <sup>5</sup>~~4~~ under the structural Formula III, "alkanoylamidoalkyl," has been deleted.

In claim 18, line <sup>12</sup>~~11~~ under the structural Formula III, the following terms have been deleted: "alkanoylamidoalkyl," and "thiol,".

In claim 18, line <sup>13</sup>~~12~~ under the structural Formula III has been rewritten as follows:  
-- alkanoyloxy, alkoxy or carboxy. --